Lisata Therapeutics Entered Into Sponsored Preclinical Research Agreement With University Of Cincinnati To Study Certepetide For Treatment Of Endometriosis
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics has entered into a sponsored preclinical research agreement with the University of Cincinnati to study the use of Certepetide for treating endometriosis.
October 28, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics has partnered with the University of Cincinnati to conduct preclinical research on Certepetide for endometriosis treatment, potentially expanding its product pipeline.
The partnership with a reputable institution like the University of Cincinnati to study Certepetide for endometriosis could lead to new treatment options and expand Lisata's product pipeline, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90